[go: up one dir, main page]

CL2018000290A1 - Antagonistas del receptor de cgrp - Google Patents

Antagonistas del receptor de cgrp

Info

Publication number
CL2018000290A1
CL2018000290A1 CL2018000290A CL2018000290A CL2018000290A1 CL 2018000290 A1 CL2018000290 A1 CL 2018000290A1 CL 2018000290 A CL2018000290 A CL 2018000290A CL 2018000290 A CL2018000290 A CL 2018000290A CL 2018000290 A1 CL2018000290 A1 CL 2018000290A1
Authority
CL
Chile
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
composite
formula
Prior art date
Application number
CL2018000290A
Other languages
English (en)
Inventor
David Andrew Coates
Kevin Charles Fortner
Steven Marc Massey
Jason Kenneth Myers
Antonio Navarro
Miles Goodman Siegel
Russell Dean Stucky
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2018000290A1 publication Critical patent/CL2018000290A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA II, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p>
CL2018000290A 2015-08-12 2018-02-01 Antagonistas del receptor de cgrp CL2018000290A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203996P 2015-08-12 2015-08-12
US201562266867P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
CL2018000290A1 true CL2018000290A1 (es) 2018-07-13

Family

ID=56684300

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000290A CL2018000290A1 (es) 2015-08-12 2018-02-01 Antagonistas del receptor de cgrp

Country Status (36)

Country Link
US (1) US9708297B2 (es)
EP (1) EP3334721B1 (es)
JP (1) JP6619503B2 (es)
KR (1) KR20180030582A (es)
CN (1) CN107922385B (es)
AU (1) AU2016304769B2 (es)
BR (1) BR112018000513A2 (es)
CA (1) CA2992622A1 (es)
CL (1) CL2018000290A1 (es)
CO (1) CO2018001383A2 (es)
CR (1) CR20180043A (es)
CY (1) CY1124413T1 (es)
DK (1) DK3334721T3 (es)
DO (1) DOP2018000042A (es)
EA (1) EA201890156A1 (es)
EC (1) ECSP18009366A (es)
ES (1) ES2875600T3 (es)
HK (1) HK1249095A1 (es)
HR (1) HRP20211013T1 (es)
HU (1) HUE055609T2 (es)
IL (1) IL256572A (es)
LT (1) LT3334721T (es)
MD (1) MD3334721T2 (es)
MX (1) MX2018001672A (es)
NZ (1) NZ738990A (es)
PE (1) PE20180655A1 (es)
PH (1) PH12018500282A1 (es)
PL (1) PL3334721T3 (es)
PT (1) PT3334721T (es)
RS (1) RS62041B1 (es)
SI (1) SI3334721T1 (es)
SV (1) SV2018005631A (es)
TN (1) TN2018000026A1 (es)
TW (1) TWI636041B (es)
WO (1) WO2017027345A1 (es)
ZA (1) ZA201800452B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201904955A (zh) * 2017-05-15 2019-02-01 美商美國禮來大藥廠 可作為cgrp受體拮抗劑之3-甲基-吡咯啶-2,5-二酮衍生物
CN110678457B (zh) * 2017-05-15 2022-08-16 伊莱利利公司 Cgrp受体拮抗剂
WO2019112024A1 (ja) * 2017-12-08 2019-06-13 キッセイ薬品工業株式会社 ピロリジン化合物
MA54823A (fr) 2019-01-24 2022-04-27 Takeda Pharmaceuticals Co Composé hétérocyclique et son utilisation
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
CN114746409A (zh) * 2019-12-12 2022-07-12 伊莱利利公司 可用作正电子发射断层扫描术的示踪剂化合物的cgrp拮抗剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015550A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
BRPI0712492A2 (pt) * 2006-06-08 2012-08-21 Boehringer Ingelheim Int uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr.
CA2680307A1 (en) * 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
WO2012129013A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9227972B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
FR3009961A1 (fr) * 2013-08-30 2015-03-06 Ct Hospitalier Universitaire De Clermont Fd Agent bloqueur des canaux cav3 dans le traitement de la douleur
WO2015161011A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Benzamide cgrp receptor antagonists

Also Published As

Publication number Publication date
IL256572A (en) 2018-02-28
PE20180655A1 (es) 2018-04-17
HRP20211013T1 (hr) 2021-10-01
CO2018001383A2 (es) 2018-05-21
TN2018000026A1 (en) 2019-07-08
PT3334721T (pt) 2021-06-17
CY1124413T1 (el) 2022-07-22
PL3334721T3 (pl) 2021-10-18
HUE055609T2 (hu) 2021-12-28
DK3334721T3 (da) 2021-06-28
KR20180030582A (ko) 2018-03-23
MX2018001672A (es) 2018-05-28
US20170044138A1 (en) 2017-02-16
CA2992622A1 (en) 2017-02-16
EP3334721B1 (en) 2021-04-28
AU2016304769A1 (en) 2018-01-25
CN107922385B (zh) 2020-09-08
SI3334721T1 (sl) 2021-08-31
ECSP18009366A (es) 2018-04-30
DOP2018000042A (es) 2018-10-31
SV2018005631A (es) 2018-04-24
WO2017027345A1 (en) 2017-02-16
EP3334721A1 (en) 2018-06-20
TW201718481A (zh) 2017-06-01
CR20180043A (es) 2018-02-22
HK1249095A1 (zh) 2018-10-26
ES2875600T3 (es) 2021-11-10
JP2018522933A (ja) 2018-08-16
BR112018000513A2 (pt) 2018-09-18
RS62041B1 (sr) 2021-07-30
CN107922385A (zh) 2018-04-17
PH12018500282A1 (en) 2018-08-13
JP6619503B2 (ja) 2019-12-11
MD3334721T2 (ro) 2021-09-30
LT3334721T (lt) 2021-07-26
ZA201800452B (en) 2019-07-31
EA201890156A1 (ru) 2018-07-31
TWI636041B (zh) 2018-09-21
US9708297B2 (en) 2017-07-18
NZ738990A (en) 2019-03-29
AU2016304769B2 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
CL2018000290A1 (es) Antagonistas del receptor de cgrp
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112017024618A2 (pt) agonistas de triazol do receptor apj.
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
MA39749A (fr) Dérivés de pipéridine-dione
ECSP17054980A (es) Inhibidores selectivos de bace1
MX372543B (es) Moduladores de receptor nuclear.
ZA201703510B (en) Antibodies, uses &amp; methods
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX386975B (es) Fármacos precursores de oxabicicloheptanos.
EP4002604A4 (en) Connector
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EP4002602A4 (en) CONNECTOR
FI11620U1 (fi) Viiraosa, erityisesti modernisoitu viiraosa
AR111665A1 (es) Derivados de 3-metil-pirrolidina-2,5-diona útiles como antagonistas del receptor cgrp
EP3870426A4 (en) DUAL WELDER
CL2017002163A1 (es) Derivado de imidazopirimidina e imidazotriazina, y composición farmacéutica que lo comprende.
MX394179B (es) Liraglutida en afecciones cardiovasculares.
EP3568388A4 (en) ANTICONVULSIVING COMPOUNDS
ITUA20163609A1 (it) &#34;micro-cogeneratore&#34;.
EA201791596A1 (ru) Пиразоловые соединения
ITUB20153493A1 (it) Attrezzatura per l&#39;applicazione di borchie.
CL2019000358S1 (es) Jarra.